Entvin (YC S22)

💊 New Molecule Approval Alert 💊 Stay updated with the latest approvals through Entvin AI! Drug Name: REVUFORJ NDA #: 218944 Active Ingredient: REVUMENIBREVUMENIB Company Name: Syndax Pharmaceuticals Submission Classification: Type 1 - New Molecular Entity Entvin AI ensures you never miss critical updates like this, helping you stay ahead in the ever-evolving pharma landscape. 💬 Schedule a call to learn more: https://lnkd.in/dkBjmhg5 Peter Ordentlich, Ariane Marolewski, Suniket Fulzele, Adi Kattuboina,

💊 New Molecule Approval Alert 💊 Stay updated with the latest approvals through Entvin AI! Here’s a key update: Drug Name: EMROSI NDA #: 219015 Active Ingredient: MINOCYCLINE HYDROCHLORIDE Company Name: Dr. Reddy's Laboratories Submission Classification: Type 5 - New Formulation or New Manufacturer Entvin AI ensures you never miss critical updates like this, helping you stay ahead in the ever-evolving pharma landscape. 💬 Schedule a call to learn more: https://lnkd.in/dkBjmhg5 #RegulatoryAffairs #EntvinAI #FDAApprovals

Every day, the FDA publishes 100s of updates—ranging from old molecule label revisions to new ANDA and NDA approvals. Regulatory professionals and scientists often find themselves overwhelmed, navigating a sea of information from various regulatory bodies. But what if you only received updates tailored to your needs? At Entvin, we’ve built an AI-powered solution that reads through all these updates and flags only the ones that matter to you. For example, today I received an email update about a new NDA approval for Nilotinib Tartrate by Azurity Pharmaceuticals Inc. This 505(b)(2) application introduces a tablet dosage form, distinct from Novartis’ capsule form for Nilotinib Hydrochloride, approved back in 2007. (A 505(b)(2) application is a streamlined FDA approval pathway for drugs that use existing data to support changes like new dosage forms, strengths, formulations, or indications.) With Entvin AI, you won’t miss insights like this—keeping your focus where it truly matters. ➡️ Let Entvin (YC S22) AI streamline your workflows and make data-driven decisions faster.

In the world of pharma, staying on top of regulatory and research updates is a constant challenge. It’s not just about finding changes; it’s about identifying those critical shifts that impact patient safety and compliance—an often time-consuming, manual task. At Entvin (YC S22), we’ve been working to transform this experience. Imagine you’re a regulatory affairs professional or scientist who’s used to sifting through endless documentation just to find one small update. Now, imagine if in a matter of minutes, an AI-driven tool pinpointed exactly where that change occurred. Take, for example, a critical update happened in this week for drug "Spravato" in the “Warnings and Precautions” section of an FDA label. This is usually like searching for a needle in a haystack. With Entvin AI, that “needle” is no longer lost—it’s instantly highlighted, ready for review. The impact? Less time spent searching, more confidence in compliance, and greater focus on advancing patient outcomes. It’s a small shift with a big difference, making it easier for professionals to stay informed and proactive. (Attached: A snapshot showing how Entvin’s platform highlights these crucial changes.)

We are at Basel for BioTechX Europe. Excited about all the conversation going to happen around LLMs in lifesciences. Drop by our booth #S57 if you want to have a quick chat. #BioTechX Entvin (YCS22), Hemant Phalak, Rishabh Arya

We're at BioTechX Europe! Stop by our booth #S57 in Startup Zone to discover how we're revolutionizing biotech with cutting-edge AI solutions. 🔬 Join us for live demos, insightful discussions, and more! Let's chat about the future of biotechnology and how collaboration can drive innovation. We can't wait to connect with industry leaders and forward-thinkers like you. See you there! 👋 Entvin (YCS22) - Sanskar Jain - Hemant Phalak - Rishabh Arya #BioTechX #Biotechnology #AI #Innovation #Entvin

Day 1 at CPHI Milan! Entvin (YCS22)- Hemant Phalak #CPHIMilan #CPHI

Just landed on a documentary about Ozempic on my flight It perfectly aligned with the theme of innovation in healthcare! Here's a brief timeline of the weight loss drug landscape, highlighting key players like Novo Nordisk and Eli Lilly and Company - 1920s-1940s: Early weight loss treatments involved organotherapy using animal gland extracts. - 1960s-1990s: A variety of weight loss drugs emerged, including amphetamines, though many were withdrawn due to safety concerns. - 1990s: Research on GLP-1 (glucagon-like peptide-1) began, revealing its role in weight loss. - 2005: Novo Nordisk’s Exenatide (Byetta) was approved by the FDA for type 2 diabetes, with weight loss noted as a side effect. - 2010: Novo Nordisk’s Liraglutide (Victoza) was approved in the US, showing better weight loss results than Byetta. - 2008: Novo Nordisk began Phase II clinical trials for semaglutide (Ozempic). 2013: The American Medical Association officially declared obesity a disease, paving the way for insurance reimbursement for obesity treatments. - 2016-2017: Clinical trials for Ozempic were conducted. - 2017: FDA approved Novo Nordisk’s Ozempic (semaglutide) for type 2 diabetes, but the drug also showed remarkable results in weight loss—a pivotal moment that reshaped its potential in obesity management. - 2018: Ozempic was approved in Canada, the EU, and Japan. - 2021: Higher-dose semaglutide (Wegovy) was approved for obesity treatment by Novo Nordisk. - 2022: Eli Lilly’s Tirzepatide (Mounjaro) was approved for type 2 diabetes. - 2023: Eli Lilly’s Zepbound (higher-dose tirzepatide) was approved for obesity, and worldwide supply shortages of semaglutide occurred due to high demand. - 2024: Ongoing research by companies like Novo Nordisk and Eli Lilly into new GLP-1 drugs and combination therapies continues. The treatment cost is a significant barrier, with Ozempic and similar drugs priced at around $12,000 per year per person. Since the treatment must be continued indefinitely to maintain weight loss, this places a long-term financial burden on patients without end to medication. The weight loss drug market has seen explosive growth, driven by the popularity of drugs like Ozempic and Wegovy. The global market is expected to exceed $100 billion by 2030, with demand continuing to rise due to the increasing prevalence of obesity and type 2 diabetes. Entvin (YCS22) #NovoNordisk #EliLilly #Ozempic #WeightLossDrugs #GLP1

Exciting News! Entvin (YCS22) is officially listed as a Start-up Exhibitor at this year’s CPHI Milan! 🚀 At Entvin, we're on a mission to transform R&D workflows in pharma and biotech with our AI-driven platform, streamlining data collection, analysis, and synthesis for greater efficiency and precision. Why should you visit our booth #6SU18? 1. Discover how we can simplify your R&D operations. 2. Learn about our AI-driven platform, which transforms raw data into actionable insights. 3. Explore the future of generic drug development, where automation meets intelligence! Drop a comment or DM us if you're coming to meet us at CPHI Milan and explore the breakthrough capabilities of Entvin. Sanskar Jain - Hemant Phalak - Rishabh Arya #CPHI #Biotech #Pharma #Innovation #AI #DrugDevelopment #Automation #Entvin

🚀 AI as a Black Box: Groundedness and Traceability in Life Sciences 🌿🤖   In life sciences, accuracy is not just important—it's critical. Whether we're developing new treatments or making vital research breakthroughs, we need to be absolutely sure about the data and the decisions derived from it. That's where the challenge of AI being a "black box" comes in.   When AI models provide results without clear explanations, it limits trust and hampers adoption, especially in a field like life sciences where transparency and traceability are essential. Imagine making a clinical decision based on an algorithm whose reasoning we can’t trace—risky, right? 🚫   At Entvin (YCS22) we have been working on a solution that demystifies this "black box" by providing references for all AI-generated answers, with highlighted answers in screenshots for easy validation. This ensures that every AI-driven insight is grounded in credible sources, making the AI's decision-making process transparent and traceable.   🔬 Why is this important?   Trust: Builds confidence in AI's decisions.   Accountability: Easily trace back steps and sources.   Compliance: Essential for regulated industries like life sciences.   Grounded and traceable AI is not just the future—it’s the present. Let’s ensure that AI  continues to innovate while being reliable and transparent. What challenges have you faced while working with different LLM models? I'd love to hear your thoughts, and feel free to reach out if you have any questions!   #AI #LifeSciences #Innovation #GroundedAI #Traceability #TrustInAI #AIInHealthcare #Transparency #AIforGood